Table 4 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and Paclitaxel in gastric cancer cell lines
YBC-2 | Combination Index Value | Parameter (μM) | ||||
|---|---|---|---|---|---|---|
Drug | ED50 | ED75 | ED90 | Dm | m | r |
TAX | Â | Â | Â | 1.24 | 0.98 | 0.9 |
HER | Â | Â | Â | 1201.02 | 0.32 | 0.92 |
TAX + HER | 6.03 | 14.77 | 36.21 | 0.85 | 0.54 | 0.82 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |
YBC-3 | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
TAX | Â | Â | Â | 9.609 | 2.129 | 0.940 |
HER | Â | Â | Â | 46.063 | 0.623 | 0.970 |
TAX + HER | 0.225 | 0.172 | 0.185 | 7.010 | 1.220 | 0.889 |
Diagnosis combined effect | synergy | synergy | synergy | Â | Â | Â |
NCI-N87 | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
TAX | Â | Â | Â | 1.49 | 1.56 | 0.96 |
HER | Â | Â | Â | 113350 | 0.19 | 0.63 |
TAX + HER | 1747.94 | 0.81 | 0 | 858.42 | −0.16 | 0.90 |
Diagnosis combined effect | antagonism | synergy | synergy | Â | Â | Â |
U-87 MG | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
TAX | Â | Â | Â | 0.79 | 0.89 | 0.87 |
HER | Â | Â | Â | 1845.53 | 0.46 | 0.86 |
TAX + HER | 361.02 | 1571.47 | 6840.35 | 1.27 | 0.41 | 0.89 |
Diagnosis combined effect | antagonism | antagonism | antagonism | Â | Â | Â |
SK-BR-3 | Combination Index Value | Parameter (μM) | ||||
Drug | ED50 | ED75 | ED90 | Dm | m | r |
TAX | Â | Â | Â | 0.42 | 1.11 | 0.96 |
HER |  |  |  | 1.42E + 06 | 0.05 | 0.43 |
TAX + HER | 0.05 | 0.24 | 1.12 | 0 | 0.44 | 0.88 |
Diagnosis combined effect | synergy | synergy | antagonism | Â | Â | Â |